Abbott, CamDiab, Ypsomed Partner on Automated Insulin Delivery

Abbott, CamDiab, and Ypsomed began a partnership to create an integrated automated insulin delivery (AID) system, with an initial focus on the European market.
 
The new integrated AID system will connect Abbott’s FreeStyle Libre 3 continuous glucose monitoring (CGM) sensor to CamDiab’s CamAPS FX mobile app, which connects with Ypsomed’s mylife YpsoPump insulin pump. The connected, smart wearable AID tech will continuously monitor glucose levels and automatically adjust and dose the correct insulin amount to remove guesswork of typical insulin dosing.
 
“Our goal is to make diabetes care as easy as possible, which is why Abbott continues to expand its team of insulin delivery partners, digital coaching and technology leaders,” Jared Watkin, senior VP of Abbott’s diabetes care business told the press. “We want to deliver new advanced solutions that simplify and make it possible for people to spend less time thinking about diabetes and more time living.”
 
“Poor glucose control leads to an increased risk of diabetes complications such as blindness, and heart and kidney disease. We want to help people with diabetes better manage their glucose through advanced technology. Our CamAPS FX, already approved in Europe, is a highly adaptive algorithm that when integrated with Abbott’s sensor is being designed to communicate with Ypsomed’s insulin pump to provide the optimal insulin dose, lifting the burden of managing a condition that is relentlessly unpredictable day and night,” said Roman Hovorka, director of CamDiab.
 
“We are convinced that major challenges of society can only be addressed through partnerships. We are therefore proud to expand our partners and connectivity to offer more freedom of choice in managing diabetes. When combined our mylife YpsoPump with the FreeStyle Libre 3 system and CamAPS FX advanced adaptive hybrid closed-loop app, we will be able to deliver an additional compact and lightweight AID system that is discreet and simple to use,” said Simon Michel, CEO of Ypsomed.
 
The companies intend to finish developing the system by the end of 2022 with commercial launch shortly thereafter.